Harbour BioMed snags $102.8m Series C
Harbour BioMed, a clinical-stage biopharmaceutical company, has raised $102.8 million in Series C financing.
Harbour BioMed, a clinical-stage biopharmaceutical company, has raised $102.8 million in Series C financing.
Copyright PEI Media
Not for publication, email or dissemination